Skip to main content
TipRanks
Go Ultimate75% OFF

SciBase Holding AB (SCIB) AI Stock Analysis

0 Followers
SE:SCIB

SciBase Holding AB

(Nasdaq OMX AB:SCIB)

Select Model
Rating:37Underperform
Price Target:SEK 9.00▼(-1.10% Downside)
Action:reiterated
Date:11/14/26

SciBase Holding AB receives the minimum possible score due to alarming financial instability, characterized by extreme cash burn and deep unprofitability. These fundamental threats are compounded by a harsh technical downtrend and weak valuation metrics, signaling extremely high risk despite top-line sales growth.

Positive Factors
Strong Revenue GrowthSustained multi-year revenue expansion indicates growing adoption of SciBase’s dermatology technology and improving commercial reach. Continued top-line growth can support operating leverage over time, provided the company converts its expanding revenue base into improved profitability.
Negative Factors
Deepening LossesLosses have widened materially despite strong revenue growth, showing that the current operating cost base is absorbing the benefits of expansion. Persistent negative margins weaken financial resilience and make future funding, scale efficiencies, and disciplined cost control increasingly important.

SciBase Holding AB (SCIB) vs. iShares MSCI Sweden ETF (EWD)

-100%-50%0%50%100%150%SE:SCIB-54.78%EWD+15.85%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 135.27M
Dividend Yield
―
Average Volume (3M)
10.26K
Price to Earnings (P/E)
-0.7
Beta (1Y)
-0.21
Revenue Growth
54.94%
EPS Growth
47.64%
Country
Sweden
Employees
46
Sector
General
Sector Strength
55
Industry
Medical - Devices

SciBase Holding AB Business Overview & Revenue Model

Company Description

SciBase Holding AB (publ), a medical technology firm founded in 1998 and headquartered in Sundbyberg, Sweden, specializes in the global development and distribution of instruments for diagnosing skin cancer and other dermatological issues. Their key...

SciBase Holding AB Financial Statement Overview

Summary

Despite robust revenue expansion and healthy gross margins, the company faces critical liquidity risks. Massive operating losses, severe cash burn, and a rapidly depleting equity base completely overshadow the top-line growth.

Income Statement

30Negative

Balance Sheet

25Negative

Cash Flow

15Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue56.68M40.46M29.70M23.25M17.89M11.73M
Gross Profit33.50M27.10M21.08M16.04M11.23M6.58M
EBITDA-98.58M-81.49M-57.64M-51.83M-39.33M-38.82M
Net Income-104.45M-87.06M-61.13M-55.59M-39.90M-41.69M
Balance Sheet
Total Assets53.37M52.17M61.73M64.33M49.85M85.46M
Cash, Cash Equivalents and Short-Term Investments13.53M22.60M11.24M34.12M18.83M65.61M
Total Debt22.50M23.03M4.18M6.80M8.12M2.86M
Total Liabilities47.74M45.51M25.08M21.28M24.62M14.66M
Stockholders Equity5.64M6.66M36.65M43.06M25.24M70.80M
Cash Flow
Free Cash Flow-103.99M-84.81M-57.81M-52.37M-44.85M-40.12M
Operating Cash Flow-102.49M-84.58M-57.38M-51.98M-44.47M-39.50M
Investing Cash Flow-1.59M-228.00K-428.00K-383.00K-381.00K-526.00K
Financing Cash Flow92.87M96.29M34.91M67.68M-2.48M64.22M

SciBase Holding AB Technical Analysis

Technical Analysis SentimentNegative
Last Price9.10

Price Trends

50DMA14.15Negative
100DMA20.60Negative
200DMA27.79Negative

Market Momentum

MACD-1.16Positive
RSI19.14Positive
STOCH12.04Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SCIB, the sentiment is Negative. The current price of 9.10 is below the 20-day moving average (MA) of 12.20, below the 50-day MA of 14.15, and below the 200-day MA of 27.79, indicating a bearish trend. The MACD of -1.16 indicates Positive momentum. The RSI at 19.14 is Positive, neither overbought nor oversold. The STOCH value of 12.04 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SCIB.

SciBase Holding AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

SE:SCIB against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:SECT.BSE:SECT.B74OutperformSEK 62.79B98.4130.26%0.71%13.94%5.70%
SE:PAXSE:PAX61NeutralSEK 1.57B-309.35-1.22%―34.05%-144.96%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
SE:SEZISE:SEZI55NeutralSEK 551.04M-5.65-35.44%―18.56%28.11%
SE:ACARIXSE:ACARIX45NeutralSEK 217.34M-5.51-96.06%―40.61%32.63%
SE:SPECSE:SPEC40UnderperformSEK 19.54M-0.11-57.15%――78.15%
SE:SCIBSE:SCIB37UnderperformSEK 135.27M-0.71-415.20%―54.94%47.64%

* General Sector Average

Performance Comparison

-50%0%50%100%SE:SCIBSE:PAXSE:SEZISE:SPECSE:SECT.BSE:ACARIXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:SCIB and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:SCIBSciBase Holding AB9.10-11.82-56.50%
SE:PAXPaxman AB66.004.006.45%
SE:SEZISenzime AB3.38-1.63-32.44%
SE:SPECSpectraCure AB0.01-0.12-89.55%
SE:SECT.BSectra AB Class B327.4046.6416.61%
SE:ACARIXAcarix AB0.17-0.10-36.76%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 14, 2026